MS

Bristol Myers Squibb's Zeposia launches into crowded MS market
Fierce Pharma
Tue, 06/2/20 - 10:50 am
Bristol-Myers Squibb
Celgene
Zeposia
drug launches
MS
multiple sclerosis
Novartis builds case for MS drug ofatumumab as FDA decision looms
Pharmaforum
Wed, 05/27/20 - 10:22 am
Novartis
ofatumumab
clinical trials
MS
multiple sclerosis
Sanofi posts data from contentious phase 2 multiple sclerosis trial
Fierce Biotech
Thu, 04/23/20 - 09:15 pm
Sanofi
clinical trials
MS
multiple sclerosis
Principia Biopharma
SAR442168
Early treatment with Novartis' Mayzent stalls secondary progressive MS: study
Fierce Pharma
Tue, 04/21/20 - 11:55 pm
Novartis
Mayzent
MS
multiple sclerosis
Gilenya
FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch
Xconomy
Thu, 03/26/20 - 10:42 am
Bristol-Meyers Squibb
Celgene
M&A
ozanimod
MS
mutliple sclerosis
drug launches
FDA
COVID-19
Zeposia
Janssen files MS pill, ahead of FDA decision on BMS’ rival
Pharmaforum
Thu, 03/19/20 - 11:06 am
Janssen
JNJ
multiple sclerosis
MS
FDA
ponesimod
Bristol-Myers Squibb
ozanimod
France’s MedDay says drug for MS falls at phase 3 hurdle
Pharmaforum
Thu, 03/12/20 - 10:54 am
MedDay Pharma
France
MD1003
multiple sclerosis
MS
clinical trials
Go or no go? Ozanimod and Fintepla await FDA verdicts
EP Vantage
Wed, 02/26/20 - 10:26 am
Bristol-Myers Squibb
ozaminod
MS
multiple sclerosis
Zogenix
Fintepla
FDA
Teva Calls on FDA to Make Copaxone a Biologic as Part of March Transition
RAPS.org
Mon, 02/24/20 - 11:47 pm
Teva Pharmaceutical
Copaxone
MS
multiple sclerosis
FDA
biologics
Novartis gets a boost in blockbuster multiple sclerosis race with Roche
Endpoints
Mon, 02/24/20 - 10:41 am
Novartis
MS
multiple sclerosis
FDA
priority reviews
Arzerra
To challenge Ocrevus, German Merck takes on Aubagio
EP Vantage
Sun, 02/23/20 - 02:00 pm
Ocrevus
Merck KGaA
Aubagio
evobrutinib
MS
multiple sclerosis
Will Biogen’s Big Patent Victory Ease Investor Worries About Its Alzheimer’s Drug?
Motley Fool
Tue, 02/11/20 - 10:36 am
Biogen
Mylan
Alzheimer's disease
patents
Tecfidera
MS
multiple sclerosis
Vumerity
Multiple Sclerosis Update: Biogen, Sanofi, Active, Adamas and Novartis
BioSpace
Sun, 02/9/20 - 04:01 pm
MS
multiple sclerosis
Biogen
Sanofi
Active Biotech
Mylan
Novartis
Adamas
Multiple sclerosis “win” makes the Principia shorts squirm
EP Vantage
Thu, 02/6/20 - 10:51 am
Principia Biopharma
SAR442168
MS
multiple sclerosis
Biogen wins Tecfidera patent challenge from Mylan, sending shares way up
Fierce Pharma
Wed, 02/5/20 - 10:25 pm
Biogen
patents
Tecfidera
Mylan
multiple sclerosis
MS
Active Biotech is back, with one last bid for the failed MS drug Teva discarded
Endpoints
Wed, 02/5/20 - 10:11 am
Teva Pharmaceutical
Active Biotech
laquinimod
MS
multiple sclerosis
GeNeuro raises €17.5M for multiple sclerosis clinical trial
Fierce Biotech
Fri, 01/31/20 - 12:18 pm
GeNeuro
MS
multiple sclerosis
clinical trials
temelimab
Patients Still Struggle To Balance High Costs Of MS Treatment, Despite Generic
NPR
Mon, 01/20/20 - 10:56 am
drug pricing
generics
MS
multiple sclerosis
New MS Trial Will be First to Compare Stem Cell Therapy with Best Available Biologics
Xtalks
Mon, 01/13/20 - 11:35 pm
stem cells
MS
multiple sclerosis
NIH
AHSCT
Biogen
Tysabri
Sanofi
Lemtrada
Roche
Ocrevus
Rituxan
Pear Therapeutics announces first patient dosed in part II of Pear-006 feasibility study
Pharmaceutical Business Review
Wed, 12/18/19 - 10:31 am
Pear Therapeutics
MS
multiple sclerosis
Pear-006
clinical trials

Pages